Presentation is loading. Please wait.

Presentation is loading. Please wait.

Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center.

Published byMildred Hunt Modified over 8 years ago

Similar presentations

Presentation on theme: "Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center."— Presentation transcript:

1 Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center

2 Scope of the Problem Inadequate Initial Antibiotic TherapyBacterial Resistance

3 Infection Distribution in Adult ICU’s Major Types of Infection (NNIS data, 1992-1997)

4 Nosocomial Infection Richards MJ et al, CCM. 1999;27:887-882

5 NNIS

6 Pathogens Most Frequently associated with Nosocomial Pneumonia in the ICU

7 Inadequate Initial Antibiotic Therapy Inadequate Initial Antibiotic Therapy

8 Initial Inadequate Therapy

9 Mortality Associated with Initial Inadequate Therapy

10 Resistant Pathogens, Inadequate Treatment and Mortality (BSI) Ibrahim EH, et al. Chest 2000;118:145-155

11 Inadequate Antimicrobial Therapy ► 2000 consecutive MICU/SICU patients ► 655 (25.8%) with infections ► 169 (8.5%) with inadequate therapy Kollef MH, et al chest. February 1999;115(2):462-474

12 Infection Classification Kollef MH, et al chest. February 1999;115(2):462-474

13 Cohort of Infected Patients and Inadequate Therapy Kollef MH, et al chest. February 1999;115(2):462-474

14 Most Common Pathogens ► Inadequate therapy (n=169)  P. aeruginosa: 53  MRSA: 45  VRE: 13 ► Adequate therapy (n=486)  Escherchia coli: 76  MSSA: 88 Kollef MH, et al chest. February 1999;115(2):462-474

15 Clinical Outcomes Kollef MH, et al chest. February 1999;115(2):462-474

16 Hospital Mortality of Infected Patients Kollef MH, et al chest. February 1999;115(2):462-474 P<0.001

17 Reduce Inappropriate Initial Antimicrobial Therapy ► Guidelines ► Broad spectrum and combination antibiotics ► ID consultation ► Automated antibiotic consultant ► More selective and sensitive diagnostic methods

18 Clinical Guidelines for the Treatment of Ventilator Associated Pneumonia ► Prospective study: 50 patients were evaluated in the before group and 52 in the after group ► Administration of vancomycin/imipenem/ciprofloxacin within 12 hours of clinical diagnosis ► Antibiotic modification after24-48 hrs ► Seven-day course of therapy (>7 days if symptoms and signs are persisted) Ibrahim EH et al. Crit Care Med, 2001;29: 1109-1115

19 Clinical Guidelines for the Treatment of Ventilator Associated Pneumonia Ibrahim EH et al. Crit Care Med, 2001;29: 1109-1115

20 Automated Antibiotic Consultant Evans Arch Int Med 1994

21 Broad-Spectrum and Combination Antibiotics Trouillet et al. Am J Res Crit Care Med. 1998;157:531-539

22 ID Consultation Byl B. Clin Inf Dis; 1989

23 Emergent Bacterial Resistance Bacterial Resistance

24 Impact of Antibiotic Restriction on Resistance Neurosurgical Intensive Care Unit in London 1968 1969 1970 All antibiotics stopped Price. Lancet. 1970

25 Decrease in Hospital-acquired ICU Infection Rates, NNIS, 1990-1999

26 Possible Explanation for Decrease in Infection Rate ► Efforts to prevent infections: new research findings, prevention guidelines ► Shift of health care from hospital-based care ► True decrease secondary to adhesion to infection control policies

27 Rates of Resistance Among Nosocomial Infections Reported in Intensive Care Patients, Comparison of 1999 (January-July) with Historical Data January-July 1999 1993-1998

28 Emerging Pathogens ► Methicillin-resistant Staphylococcus aureus (MRSA) ► Methicillin-resistant Staphylococcus epidermitis (MRSE) ► Vancomycin-resistant enterococci (VRE) ► Vancomycin-intermediate Staphylococcus aureus (VISA) ► Extended-spectrum beta-lactamase (ESBL)-producing gram-negative organisms ► Multidrug-resistant Acinetobacter spp.

29 Antibacterial Resistance in Nosocomial Infections Gram-Negative Pathogens Fridkin and Gaynes. Clin Chest Med. 1999:20:302-315

30 Antibacterial Resistance in Nosocomial Infections Gram-Positive Pathogens Fridkin and Gaynes. Clin Chest Med. 1999:20:302-315

31 Methicillin Resistant Staphylococci by setting Fridkin. Clin Infect Dis.1999

32 Vancomycin-resistant Staphylococcus aureus ► June 2202- First case of VRSA isolated from a swab obtained from a catheter exit site ► The isolate was resistant to:  Oxacillin (MIC >16 µg/ml)  Vancomycin (MIC >128 µg/ml) ► The isolate contained:  The oxacillin-resistant gene mecA  The vanA vancomycin resistant gene from enterococci CDC MMWR. 2002;51:565-567

33 Epidemiology of VRE ► Present in all 50 states in the United States ► Number of isolated continues to grow ► Recognized in Europe, Japan, Central and South America ► Resistance to alternate antibiotic therapy continues to be a problem

34 Risk Factors for VRE ► Prior broad spectrum antibiotics (especially cephalosporins and vancomycin) ► Prolonged hospitalization ► Immunocompromised host ► Neutropenia ► Admission to an intensive care unit ► Renal failure requiring dialysis Noskin. J Lab Clin Med. 1997

35 Antibiotics and Colonization with VRE Ostrowsky. Arch Intern Med. 1999

36 Use of Vancomycin in US and Rate of VRE Kirsl et al. Historical usage of vancomycin. Antimicrob Agent Chemo 1998 National Nosocomial Infection Surveillance System (CDC)

37 Independent Predictors of Vancomycin- Resistant Enterococci in Adult Intensive Care Units NNIS

38 Enterococcal Resistance by Species Jones. Diagn. Microbiol Infect Dis. 1998

39 Outcome of Enterococcus faecium Bacteremia Stosor. Arch Intern Med. 1998

40 Extended Spectrum  - lactamases ESBLs ► ESBL inactivates oxyamino beta-lactams and fourth-generation cephalosporins (to some extent) and aztreonam ► Large plasmids encoding multiple antibiotic resistance determinants including aminoglycoside modifying enzymes ► Strains producing ESBL are typically sensitive to cephamycins and carbapenems ► Common ESBL-producers: K. pneumoniae, and less common other Enterobactericae

41

42 K. pneumoniae Resistant to Extended- Spectrum  -lactam (ESBL) at NNIS Evidence of Inter-hospital Transmission Infect Control Hosp Epidemiolo Mannel DL, et al. Infect Control Hosp Epidemiolo 1997

43 Emergence of Carbapenem- resistant Acinetobacter spp. ► Frequent use of aminoglycosides, fluroquinolones, ureidopenicillins and third generation cephalosporins ► Reported from South America, Europe, Far East, Middle East, and United States ► Numerous outbreaks (some strains susceptible only to polymyxin B) ► High mortality rates ► Endemic in some hospitals

44 Endemic Carbapenem-Resistant Acinetobacter spp. In Brooklyn, New York ► 15 hospitals ► November 1997, all aerobic bacteria collected ► Acinetobacter spp. (233) accounted for 10% of the gram negative bacilli ► Carbapenem resistance ranged from 0-100% ► 10% of isolated were susceptible only to polymyxin ► Risk factors  Use of third generation cephalosporins plus aztreonam  Environment and healthcare worker hands contamination documented  PFGE documented inter- and intra-hospital spread VM Manikal et al. CID. 2000

45 Antimicrobial Susceptibility of 233 Acinetobacter spp., 15 Hospital, Brooklyn, New York VM Manikal et al. CID. 2000

46 Efforts to Decrease the Rate of Emergent Antimicrobial Resistance ► CDC guidelines and barrier precautions ► Antibiotic restriction ► Selective bowel decontamination ► Rotation antibiotics ► Short course antibiotic course

47 Impact of CDC Guidelines on Endemic VRE M. Montecalvo et al. Ann Int Med. 1999 J Morris et al. Ann Int Med. 1995 E Jochimsen et al. ICHE 1999

48 Impact of Formulary Change on VRE Empiric therapy for febrile neutropenia Lisgaris. IDSA (abstract). 2000

49 Bradley. JAC. 1999 Prevention of GRE Therapy for Febrile Neutropenia ► Purpose: reduce glycopeptide resistant enterococci (GRE) ► Situation: 50% colonization rate in oncology units ► Methods:  Phase 1: no intervention (ceftazidime)  Phase 2a and 2b: replace ceftazidime with piperacillin/tazobactam  Phase 3: return to ceftazidime

50 Results Phase 1 vs 2b (P<0.001) Bradley. JAC. 1999

51 Antimicrobial Utilization and Resistance ► Interdisciplinary team in Indianapolis to control resistant organisms ► Interventions:  Reduce third generation cephalosporin use  Reduce imipenem use  Encourage use of ampicillin/sulbactam and piperacillin/tazobactam  Enhance compliance with infection control  Education regarding antimicrobial resistance

52 Antimicrobial Utilization and Resistance  Piperacillin/tazobactam resistant Smith. Pharmacotherapy 1999

53 Impact of Formulary Changes on MRSA and Ceftazidime Resistant K. Pneumoniae ► Reduce usage of cephalosporins, imipenem, clindamycin and vancomycin ► Increased use of  - lactam/  -lactamase inhibitors Landman. Clin. Infect Dis. 1999

54 Ceftazidime Resistant K. pneumoniae Cleveland VA Medical Center

55 Impact of a Rotating Empiric Antibiotic Schedule on Infectious Mortality in an Intensive Care Unit Raymond DP. Crit Care Med 01-Jun-2001, 29(6);1101-8

56 Impact of a Rotating Empiric Antibiotic Schedule on Infectious Mortality in an Intensive Care Unit Raymond DP. Crit Care Med 01-Jun-2001, 29(6);1101-8

57 Short Course Antibiotic Therapy Hospital Acquired Pneumonia Clinical Pulmonary Infection Score (CPIS) <6 >6 Antibiotics 10-21 days Ciprofloxacin 3 days Antibiotics 10-21 days <6 D/C >6 treat as pneumonia Reevaluate CPIS at 3 days Singh N, et al. Am J Resp Crit Care Med. 2000;162:505-511

58 Short Course Antibiotic Therapy Hospital Acquired Pneumonia Singh N, et al. Am J Resp Crit Care Med. 2000;162:505-511

59 In Conclusion:

60 Reduce Inappropriate Initial Antimicrobial Therapy ► Guidelines and goal directed protocols ► Broad spectrum and combination antibiotics ► ID consultation ► Automated antibiotic consultant! ► More selective and sensitive diagnostic methods

61 Efforts to Decrease the Rate of Emergent Antimicrobial Resistance ► CDC guidelines and barrier precautions ► Antibiotic restriction and appropriate utilization:  Decrease cephalosporin use  Increase extended-spectrum penicillin/beta- lactamase inhibitor use  Limit carbapenem and vancomycin use to desired therapy ► Selective bowel decontamination ► Rotation antibiotics ► Short course antibiotic course: HAP

62 Conclusion Judicious Use of Antimicrobial ► Decrease cephalosporin use ► Increase extended-spectrum penicillin/beta-lactamase inhibitor use ► Limit carbapenem and vancomycin use to desired therapy

63 Handwashing compared to Alcohol Hand

Download ppt "Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center."

Similar presentations

NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS

NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.

ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.
East Texas Medical Center – Tyler Annual Physician Education MDRO -Multidrug-Resistant Organisms- Revised: April 2013.

East Texas Medical Center – Tyler Annual Physician Education MDRO -Multidrug-Resistant Organisms- Revised: April 2013.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.

Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Role of MRSA Swabs for De-escalation of Antibiotics in HCAP

Role of MRSA Swabs for De-escalation of Antibiotics in HCAP
H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.

1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.

Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.

Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.
Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients L. Silvestry et al.

Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients L. Silvestry et al.
Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.

Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.
Enoch Omonge University of Nairobi

Enoch Omonge University of Nairobi
Antibiotic Resistance why do we care? Thursday 1/10/2008.

Antibiotic Resistance why do we care? Thursday 1/10/2008.
What intervention on the use or dosing of antibiotics work to decrease resistance? Jan. 18, 2007 Sung-Ching Pan.

What intervention on the use or dosing of antibiotics work to decrease resistance? Jan. 18, 2007 Sung-Ching Pan.
APIC Chapter 13 Journal Club April 15, 2015

APIC Chapter 13 Journal Club April 15, 2015
Massimo Antonelli, MD Dept. of Intensive Care & Anesthesiology Università Cattolica del Sacro Cuore Rome - Italy Antibiotics: The old and the new.

Massimo Antonelli, MD Dept. of Intensive Care & Anesthesiology Università Cattolica del Sacro Cuore Rome - Italy Antibiotics: The old and the new.
Surprising Victories Against Old Foes: New Hope for Prevention and Control of Healthcare- Associated MRSA Infections John A. Jernigan, MD, MS Division.

Surprising Victories Against Old Foes: New Hope for Prevention and Control of Healthcare- Associated MRSA Infections John A. Jernigan, MD, MS Division.
Eunice Huang, MD, MS APSA Education Day Palm Desert, CA May 22, 2011

Eunice Huang, MD, MS APSA Education Day Palm Desert, CA May 22, 2011
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.

MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
Epidemiology and Control of Methicillin-Resistant Staphylococcus aureus in hospitals Maria Kapi,MD Registrar of Medical Microbiology Laiko General Hospital.

Epidemiology and Control of Methicillin-Resistant Staphylococcus aureus in hospitals Maria Kapi,MD Registrar of Medical Microbiology Laiko General Hospital.

Similar presentations

Ads by Google